Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors

Neoplasia

Volumn 10, Issue 5, 2008, Pages 489-500

  Kuwai, Toshio ^a   Nakamura, Toru ^a   Sasaki, Takamitsu ^a   Kim, Sun Jin ^a   Fan, Dominic ^a   Villares, Gabriel J ^a   Zigler, Maya ^a   Wang, Hua ^a   Bar Eli, Menashe ^a   Kerbel, Robert S ^b   Fidler, Isaiah J ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IRINOTECAN; LENTIVIRUS VECTOR; PHOSPHOPROTEIN; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; SHORT HAIRPIN RNA; SODIUM CHLORIDE; TRANSFORMING GROWTH FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; GENE MUTATION; HUMAN; HUMAN CELL; MALE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR NECROSIS;

EID: 43249092388     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.08200     Document Type: Article

References (50)

1. IJ Fidler The organ microenvironment and cancer metastasis Differentiation 70 2002 498 505 (Review).
2. IJ Fidler The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited Nat Rev Cancer 3 2002 453 458 (Timeline).
3. RS Kerbel J Folkman Clinical translation of angiogenesis inhibitors Nat Rev Cancer 2 2002 727 739
4. KP De Jong R Stelleman A Karrenbeld J Koudstaal AS Gouw WJ Sluiter PM Peters MJ Slooff EG DeVries Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors Hepatology 28 1998 971 979
5. L Toschi F Cappuzzo Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors Oncologist 12 2007 211 220
6. D Veale N Kerr GJ Gibson PJ Kelly AL Harris The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long-term survival Br J Cancer 68 1993 162 165
7. A Rajput AP Korterba JI Kreisberg JM Foster JK Willson MG Brattain A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo Cancer Res 67 2007 665 673
8. F Ciardiello R Bianco V Damiano G Fontanini R Caputo G Romatico S De Placido AR Bianco J Mendelsohn G Tortora Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells Clin Cancer Res 6 2000 3739 3747
9. MD Marmor KB Skaria Y Yarden Signal transduction and oncogenesis by ErbB/HER receptors Int J Radiat Oncol Biol Phys 58 2004 903 913
10. N Ravindranath D Wion P Brachet D Djakiew Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate J Androl 22 2001 432 443
11. CJ Bruns CC Solorzano MT Harbison S Ozawa R Tsan D Fan J Abbruzzese P Traxler E Buchdunger R Radinsky Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma Cancer Res 60 2000 2926 2935
12. SJ Kim H Uehara T Karashima DL Shepherd JJ Killion IJ Fidler Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice Clin Cancer Res 9 2003 1200 1210
13. SJ Kim H Uehara S Yazici JE Busby T Nakamura J He M Maya C Logothetis P Mathew SJ Kim Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer J Natl Cancer Inst 98 2006 783 793
14. J Baselga CL Arteaga Critical update and emerging Rtrends in epidermal growth factor receptor targeting in cancer J Clin Oncol 23 2005 2445 2459
15. MG Kris RB Natale RS Herbst TJ Lynch Jr D Prager CP Belani JH Schiller K Kelly H Spiridonidis A Sandler Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial JAMA 290 2003 2149 2158
16. FA Shepherd J Rodriguez-Pereira T Ciuleanu EH Tan V Hirsh S Thongprasert D Campos S Maoleekoonpiroj M Smiley R Martins Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132
17. L Daniele L Macri M Schena D Dongiovanni L Bonello E Armando L Ciuffreda O Bertetto G Bussolati A Sapino Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens Mol Cancer Ther 6 2007 1223 1229
18. A Marchetti C Martella L Felicioni F Barassi S Salvatore A Chella PP Camplese T Iarussi F Mucilli A Mezzetti EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment J Clin Oncol 23 2005 857 865
19. W Pao V Miller M Zakowski J Doherty K Politi I Sarkaria B Singh R Heelan V Rusch L Fulton EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci USA 101 2004 13306 13311
20. SW Han TY Kim PG Hwang S Jeong J Kim IS Choi DY Oh JH Kim DW Kim DH Chung Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib J Clin Oncol 23 2005 2493 2501
21. TJ Lynch DW Bell R Sordella S Gurubhagavatula RA Okimoto BW Brannigan PL Harris SM Haserlat JG Supko FG Haluska Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
22. JG Paez PA Janne JC Lee S Tracy H Greulich S Gabriel P Herman FJ Kaye N Lindeman TJ Boggon EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
23. MS Tsao A Sakurada JC Cutz C-Q Zhu S Kamel-Reid J Squire I Lorimer T Zhang N Liu A Lagarde Erlotinib in lung cancer: molecular and clinical predictors of outcome N Engl J Med 353 2005 133 144
24. F Cappuzzo M Varella-Garcia H Shigematsu I Domenichini S Bartolini GL Ceresoli E Rossi V Ludovini V Gregorc L Toschi Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients J Clin Oncol 23 2005 5007 5018
25. CH Baker D Kedar MF McCarty R Tsan KL Weber CD Bucana IJ Fidler Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas Am J Pathol 161 2002 929 938
26. K Yokoi SJ Kim PH Thaker S Yazici DH Nam J He T Sasaki PJ Chiao GM Sclabas JL Abbruzzese Induction of apoptosis in tumorassociated endothelial cells and therapy of orthotopic human pancreatic carcinoma in nude mice Neoplasia 7 2005 696 704
27. K Yokoi PH Thaker S Yazici RR Rebhun DH Nam J He SJ Kim JL Abbruszzese SR Hamilton IJ Fidler Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model Cancer Res 65 2005 3716 3725
28. IJ Fidler Antivascular therapy of cancer metastasis J Surg Oncol 94 2006 178 180 (Editorial Commentary).
29. TC Windham NU Parikh DR Siwak JM Summy DJ McConkey AJ Kraker GE Gallick Src activation regulates anoikis in human colon tumor cell lines Oncogene 21 2002 7797 7807
30. K Morikawa SM Walker JM Jessup IJ Fidler In vivo selection of highly metastatic cells from surgical specimens of different primary human colon carcinoma implanted into nude mice Cancer Res 48 1988 1943 1948
31. M Wiznerowicz D Trono Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference J Virol 77 2003 8957 8961
32. P Traxler PR Allegrini R Brandt J Bruegen R Cozens D Fabbro K Grosios HA Lane P McSheehy J Mestan AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity Cancer Res 64 2004 4931 4941
33. Y Kitadai T Sasaki T Kuwai T Nakamura CD Bucana IJ Fidler Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma Am J Pathol 169 2006 2054 2065
34. L Saltz Epidermal growth factor receptor-negative colorectal cancer: is there truly such an entity? Clin Colorectal Cancer 5 2005 S98 S100
35. CH Baker MS Pino IJ Fidler Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells in human renal cell carcinoma is a primary target for therapy by tyrosine kinase inhibitors Neoplasia 8 2006 470 476
36. SJ Kim H Uehara S Yazici RR Langley J He R Tsan D Fan JJ Killion IJ Fidler Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice Cancer Res 64 2004 4201 4208
37. L Macri D Silverstein RA Clark Growth factor binding to the pericellular matrix and its importance in tissue engineering Adv Drug Deliv Rev 59 2007 1381
38. S Yazici SJ Kim JE Busby J He P Thaker K Yokoi D Fan IJ Fidler Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice Prostate 65 2005 203 215
39. PH Thaker S Yazici MB Nilsson K Yokoi RZ Tsan J He SJ Kim IJ Fidler AK Sood Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors Clin Cancer Res 11 2005 4923 4933
40. OG Yigitbasi MN Younes D Doan SA Jasser BA Schiff CD Bucana BN Bekele IJ Fidler JN Myers Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade Cancer Res 64 2004 7977 7984
41. KY Chung J Shia NE Kemeny M Shah GK Schwartz A Tse A Hamilton D Pan D Shrag L Schwartz Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry J Clin Oncol 23 2005 1803 1810
42. M Hebbar A Wacrenier C Desauw O Romano S Cattan JP Triboulet FR Pruvot Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer Anticancer Drugs 17 2006 855 857
43. R Wild K Fager C Flefleh D Kan A Camuso K McGlinchey WC Rose Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels Mol Cancer Ther 5 2006 104 113
44. IJ Fidler S Yano RD Zhang T Fujimaki CD Bucana The seed and soil hypothesis: vascularization and brain metastases Lancet Oncol 3 2002 53 57
45. J Folkman What is the evidence that tumors are angiogenesis-dependent? J Natl Cancer Inst 82 1990 4 6
46. LM Ellis W Liu SA Ahmad F Fan YD Jung RM Shaheen N Reinmuth Overview of angiogenesis: biologic implications for antiangiogenic therapy Semin Oncol 28 2001 94 104
47. RR Langley IJ Fidler Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis Endocr Rev 28 2007 297 321
48. A Eberhard S Kahlert V Goede B Hemmerlein KH Plate GH Augustin Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies Cancer Res 60 2000 1388 1393
49. SR Datta H Dudek X Tao S Masters H Fu Y Gotoh ME Greenberg Akt phosphorylation of BAD couple survival signals to the cell-intrinsic death machinery Cell 91 1997 231 241
50. RR Langley D Fan RZ Tsan R Rebhun J He SJ Kim IJ Fidler Activation of the platelet-derived growth factor receptor enhances survival of murine bone endothelial cells Cancer Res 64 2004 3727 3730